Zealand Pharma A/S (CPH:ZEAL)
Denmark
· Delayed Price · Currency is DKK 255.80
+20.90 (8.90%)
At close: Mar 9, 2026
Zealand Pharma Balance Sheet
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 4,577 | 726.03 | 449.31 | 1,069 | 1,129 | Upgrade
|
| Trading Asset Securities | 10,532 | 7,500 | 1,184 | 108.61 | 299.04 | Upgrade
|
| Cash & Short-Term Investments | 15,109 | 8,226 | 1,633 | 1,178 | 1,428 | Upgrade
|
| Cash Growth | 83.67% | 403.72% | 38.65% | -17.53% | 13.56% | Upgrade
|
| Accounts Receivable | 174.21 | 87.17 | 97.8 | 115.62 | 153.45 | Upgrade
|
| Other Receivables | 145.47 | 97.44 | 40.99 | 21.6 | 21.56 | Upgrade
|
| Receivables | 319.69 | 184.61 | 138.8 | 137.22 | 175.02 | Upgrade
|
| Inventory | - | 10.7 | 7.94 | 1.29 | 118.44 | Upgrade
|
| Prepaid Expenses | 241.62 | 106.39 | - | - | - | Upgrade
|
| Total Current Assets | 15,670 | 8,528 | 1,780 | 1,316 | 1,722 | Upgrade
|
| Property, Plant & Equipment | 151.43 | 125.25 | 149.85 | 165.49 | 221.45 | Upgrade
|
| Long-Term Investments | - | 819.63 | 21.38 | 37.84 | 26.91 | Upgrade
|
| Other Intangible Assets | 44.97 | 12.62 | 12.26 | - | 53.79 | Upgrade
|
| Long-Term Accounts Receivable | - | - | 6.89 | 18.11 | 29.09 | Upgrade
|
| Long-Term Deferred Tax Assets | 0.87 | 0.99 | 0.93 | 2.02 | 13.53 | Upgrade
|
| Other Long-Term Assets | 81.41 | 19.41 | 8.91 | - | 1.27 | Upgrade
|
| Total Assets | 15,949 | 9,506 | 1,980 | 1,540 | 2,068 | Upgrade
|
| Accounts Payable | 256.62 | 181.28 | 91.61 | 180.76 | 266.39 | Upgrade
|
| Accrued Expenses | 114.57 | 93.66 | 51.73 | - | - | Upgrade
|
| Current Portion of Leases | 22.63 | 16.04 | 16.66 | 14.73 | 14.9 | Upgrade
|
| Current Unearned Revenue | 65.34 | - | - | - | 53.03 | Upgrade
|
| Other Current Liabilities | 205.8 | 112.5 | 124.59 | - | - | Upgrade
|
| Total Current Liabilities | 664.97 | 403.47 | 284.58 | 195.49 | 334.32 | Upgrade
|
| Long-Term Debt | 302.92 | 285.33 | - | 401.35 | 647.91 | Upgrade
|
| Long-Term Leases | 80.21 | 90.39 | 102.58 | 108 | 124.63 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | - | 14.55 | Upgrade
|
| Other Long-Term Liabilities | 70.08 | 109.67 | - | 19.06 | 18.43 | Upgrade
|
| Total Liabilities | 1,118 | 888.86 | 387.15 | 723.9 | 1,140 | Upgrade
|
| Common Stock | 71.52 | 71.02 | 58.75 | 51.7 | 43.63 | Upgrade
|
| Additional Paid-In Capital | 14,729 | 14,681 | 6,406 | 4,921 | - | Upgrade
|
| Retained Earnings | 6.29 | -6,157 | -4,895 | -4,172 | - | Upgrade
|
| Comprehensive Income & Other | 23.38 | 22.39 | 22.7 | 14.62 | 884.17 | Upgrade
|
| Shareholders' Equity | 14,831 | 8,617 | 1,593 | 815.91 | 927.8 | Upgrade
|
| Total Liabilities & Equity | 15,949 | 9,506 | 1,980 | 1,540 | 2,068 | Upgrade
|
| Total Debt | 405.77 | 391.76 | 119.23 | 524.08 | 787.43 | Upgrade
|
| Net Cash (Debt) | 14,703 | 8,654 | 1,514 | 653.77 | 640.72 | Upgrade
|
| Net Cash Growth | 69.90% | 471.66% | 131.55% | 2.04% | -43.17% | Upgrade
|
| Net Cash Per Share | 205.50 | 130.26 | 26.75 | 14.15 | 14.95 | Upgrade
|
| Filing Date Shares Outstanding | 70.61 | 70.65 | 58.38 | 51.47 | 43.22 | Upgrade
|
| Total Common Shares Outstanding | 70.61 | 70.65 | 58.38 | 51.47 | 43.22 | Upgrade
|
| Working Capital | 15,005 | 8,124 | 1,495 | 1,121 | 1,387 | Upgrade
|
| Book Value Per Share | 210.04 | 121.96 | 27.28 | 15.85 | 21.47 | Upgrade
|
| Tangible Book Value | 14,786 | 8,604 | 1,581 | 815.91 | 874.01 | Upgrade
|
| Tangible Book Value Per Share | 209.41 | 121.78 | 27.07 | 15.85 | 20.22 | Upgrade
|
| Machinery | 108.22 | 84.91 | 78.57 | 82.83 | 106.63 | Upgrade
|
| Construction In Progress | - | - | - | 0.87 | 12.11 | Upgrade
|
| Leasehold Improvements | 41.52 | 39.3 | 38.91 | 38.19 | 36.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.